Induction of ErbB-3 Expression by α6β4 Integrin Contributes to Tamoxifen Resistance in ERβ1-Negative Breast Carcinomas

Valentina Folgiero, Paolo Avetrani, Giulia Bon et al. · 2008

Read Induction of ErbB-3 Expression by α6β4 Integrin Contributes to Tamoxifen Resistance in ERβ1-Negative Breast Carcinomas by Valentina Folgiero, Paolo Avetrani, Giulia Bon et al. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0001592.txt.

Description

Valentina Folgiero and co-authors wrote a 2008 PLOS ONE study on why a breast cancer drug stops working. Tamoxifen is the most used hormone drug for breast cancer. Its gains in added care are well logged in large trials. Yet many tumors learn to resist it. The team traced one route to that resistance.

They show a surface complex switches on a kin receptor that helps tumors dodge the drug. That receptor's rise marks a shift in the tumor's growth drives. Blocking the route could restore the old drug's power. The work gives drug teams a paired target to test in resistant cases.

Catalog record

CREATORValentina Folgiero, Paolo Avetrani, Giulia Bon et al.
YEAR2008
COLLECTIONPAPERS
FORMATTXT
FILE SIZE50 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0001592

Browse the full library · About the Tower of Babel